Inflammatory arthritis and sicca syndrome induced by nivolumab and ipilimumab

OBJECTIVES: Immune checkpoint inhibitors (ICIs) targeting the cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) and programmed cell death protein 1 (PD-1) pathways have demonstrated survival improvements in multiple advanced cancers, but also cause immune-related adverse events (IRAEs). IRAEs wit...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:Ann Rheum Dis
Auteurs principaux: Cappelli, Laura C, Gutierrez, Anna Kristina, Baer, Alan N, Albayda, Jemima, Manno, Rebecca L, Haque, Uzma, Lipson, Evan J, Bleich, Karen B, Shah, Ami A, Naidoo, Jarushka, Brahmer, Julie R, Le, Dung, Bingham, Clifton O
Format: Artigo
Langue:Inglês
Publié: 2016
Sujets:
Article
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC5333990/
https://ncbi.nlm.nih.gov/pubmed/27307501
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/annrheumdis-2016-209595
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires